

Welcome to STN International! Enter x:x

LOGINID:ssspal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded
NEWS 5 SEP 29 DISSABS now available on STN
NEWS 6 OCT 10 PCTFULL: Two new display fields added
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9 NOV 24 MSDS-CCOHS file reloaded
NEWS 10 DEC 08 CABA reloaded with left truncation
NEWS 11 DEC 08 IMS file names changed
NEWS 12 DEC 09 Experimental property data collected by CAS now available
in REGISTRY
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 14 DEC 17 DGENE: Two new display fields added
NEWS 15 DEC 18 BIOTECHNO no longer updated
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer
available
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS
databases
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19 DEC 22 ABI-INFORM now available on STN

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:51:48 ON 13 JAN 2004

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:52:00 ON 13 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2004 HIGHEST RN 636558-22-0
DICTIONARY FILE UPDATES: 11 JAN 2004 HIGHEST RN 636558-22-0

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading 09815362g.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:52:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2635 TO ITERATE

38.0% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 49622 TO 55778
PROJECTED ANSWERS: 78 TO 554

L2 6 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:52:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 51880 TO ITERATE

100.0% PROCESSED 51880 ITERATIONS
SEARCH TIME: 00.00.01

267 ANSWERS

L3 267 SEA SSS FUL L1

=> s l3 and caplus/lc

32498121 CAPLUS/LC

L4 258 L3 AND CAPLUS/LC


=> s l3 not l4

L5 9 L3 NOT L4

=> d l5 1-9

L5 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 337534-09-5 REGISTRY
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-, (-)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H20 N2 O2
 CI COM
 SR CA


Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 336103-05-0 REGISTRY
 CN 2-Naphthalenecarboxamide, 6-{(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl}-N-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H23 N3 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 336102-60-4 REGISTRY
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (+)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H21 N3 O2
 CI COM
 SR CA


Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 336102-58-0 REGISTRY
 CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H22 N2 O2
 CI COM
 SR CA

Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 247173-10-0 REGISTRY
 CN 1H-Imidazole-4-methanol, .alpha.-(1,1-dimethylethyl)-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H22 N2 O2
 CI COM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 247173-08-6 REGISTRY
 CN 1H-Imidazole-4-methanol, .alpha.-cyclopropyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C18 H18 N2 O2
 CI COM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 150560-49-9 REGISTRY
 CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C30 H30 N2 O3
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 75601-48-8 REGISTRY
 CN Methanone, 1H-imidazol-4-yl[[4b,5,6,7,8,8a,9,10-octahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl]-, [4bS-(4b.alpha.,8.alpha.,8a.beta.)]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H30 N2 O
 LC STN Files: BEILSTEIN*, SPECINFO
 (*File contains numerically searchable property data)


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 75601-29-5 REGISTRY
CN Methanone, {4b,5,6,7,9,10-hexahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl}-1H-imidazol-4-yl-, (4bS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H28 N2 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

176.20

176.41

FILE 'CAPLUS' ENTERED AT 07:52:59 ON 13 JAN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jan 2004 VOL 140 ISS 3

FILE LAST UPDATED: 12 Jan 2004 (20040112/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4


L6 33 L4

=> d ibib abs hitstr 1-33

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:951005 CAPLUS
 DOCUMENT NUMBER: 140:5050
 TITLE: Preparation of 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of alpha-2B and alpha-2C adrenergic receptors
 INVENTOR(S): Chow, Ken; Heidelbaugh, Todd; Gil, Daniel; Garot, Michael; Wheeler, Larry A.; Nguyen, Phong X.; Gomez, Dario G.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 163 pp.
 CODEN: PIXXD2
 PATENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099795	A1	20031204	WO 2003-US15441	20030516
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-153328 A 20020521
 GI



AB The title compds. [I: Y in the ring is optional and represents a heteroatom selected from N, O and S with the proviso that the N atom is trivalent, and the O or S atoms are divalent; m = 0, 1; n, p = 0, 1, 2; X = O, S; the dashed lines represent a bond, or absence of bond with the proviso that only one double bond is present in the ring and that two adjoining dashed lines do not both represent a bond; R1-R4 = independently H, (un)substituted Ph, C1-4 alkyl, C3-5 cycloalkyl, CH2CN, CH2SR5, CH2NR6R6, COR5, CH2OR5, OR6, SR6, NR6R6, C2-4 alkenyl or alkynyl, F, Cl, Br, Iodo, CF3, cyano, an oxygen double bonded to the ring carbon with the proviso that the adjacent dashed line within the ring represents absence of a bond; R5 = H, OR7, C1-4 alkyl, CF3, C3-6 cycloalkyl, (un)substituted


L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Ph or 5 or 6 membered heteroaryl having 1 to 3 heteroatoms selected from O, S, and N; R6 = H, C1-4 alkyl, allyl, C3-6 cycloalkyl, (un)substituted Ph or 5 or 6 membered heteroaryl having 1 to 3 heteroatoms selected from O, S, and N; R7 = H, C1-4 alkyl, allyl, C3-6 cycloalkyl, (un)substituted phenyl; R1 and R2 or R3 and R4 or R3 and R4 together can form a ring together with the resp. carbons to which each of these is attached; R10 = H, C1-6 or alkyl are prepd. These compds. possess specific or selective binding activity to .alpha.2B and/or .alpha.2C adrenergic receptors in preference over .alpha.A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedative activity. They are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviation of conditions which are responsive to treatment by agonists of .alpha.B adrenergic receptors. The diseases and conditions include pain, allodynia, chronic pain, visceral pain, neuropathic pain, corneal pain, glaucoma, elevated intraocular pressure, ischemic neuropathies, neurodegenerative diseases, diarrhea, nasal congestion, muscle spasticity, diuresis, withdrawal syndromes, optic neuropathy, spinal ischemia, stroke, memory and cognition deficits, attention deficit disorder, psychoses, manic disorders, anxiety, depression, hypertension, congestive heart failure, cardiac ischemia, arthritis, spondylitis, gouty arthritis, osteoarthritis, juvenile arthritis, autoimmune diseases, lupus erythematosus, chronic gastrointestinal inflammations, Crohn's disease, gastritis, irritable bowel disease (IBD), functional dyspepsia and ulcerative colitis. For example, 4-(4-methylindan-2-yl)-1,3-dihydroimidazole-2-thione showed agonist activity on .alpha.2B and .alpha.2C adrenergic receptors with EC50 of 3 and 13 nM, resp. and no activity on .alpha.2A adrenergic receptor.
 IT 157058-52-1P 628732-24-1P 628732-25-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
 RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 628732-24-1 CAPLUS
 CN Acetonitrile, [3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-1(2H)-naphthalenyldiene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 628732-25-2 CAPLUS
 CN Acetonitrile, [3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-1(2H)-naphthalenyldiene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 628730-35-8P 628730-36-9P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
 RN 628730-35-8 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 628730-36-9 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


IT 423773-40-4P 628730-38-1P 628730-40-5P
 628730-44-9P 628730-45-0P 628730-46-1P
 628730-47-2P 628730-48-3P 628730-49-4P
 628730-50-7P 628730-51-8P 628730-52-9P
 628730-53-0P 628730-88-1P 628731-16-8P
 628731-17-9P 628731-32-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
 RN 423773-40-4 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (9CI) (CA INDEX NAME)



RN 628730-38-1 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-4-methyl-, (9CI) (CA INDEX NAME)




RN 628730-40-5 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-6-hydroxy-, (9CI) (CA INDEX NAME)




RN 628730-44-9 CAPLUS
 CN 2H-Imidazole-2-thione, 1,3-dihydro-4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 628730-45-0 CAPLUS
CN 2H-imidazole-2-thione, 1,3-dihydro-4-[[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 628730-46-1 CAPLUS
CN 2H-imidazole-2-thione, 1,3-dihydro-4-[[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 628730-47-2 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4,5,6,7,8-hexahydro- (9CI) (CA INDEX NAME)




RN 628730-48-3 CAPLUS
CN 2H-imidazole-2-thione, 1,3-dihydro-4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 628730-49-4 CAPLUS
CN 2H-imidazole-2-thione, 1,3-dihydro-4-[[[(2R)-1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 628730-50-7 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 628730-51-8 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-8-methyl- (9CI) (CA INDEX NAME)




RN 628730-52-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-8-fluoro-3,4-dihydro- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 628730-53-0 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-6-fluoro-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 628730-88-1 CAPLUS
CN 1(2H)-Naphthalenone, 8-chloro-2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 628731-16-8 CAPLUS
CN Acetonitrile, [2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-1(2H)-naphthalenylidene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 628731-17-9 CAPLUS
CN Acetonitrile, [2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-1(2H)-naphthalenylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 628731-32-8 CAPLUS
CN 2H-imidazol-2-one, 1,3-dihydro-4-[(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




IT 226571-13-7P
RL FUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREF (Preparation); RACT (Reactant or reagent)
(prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
RN 226571-13-7 CAPLUS
CN 1H-imidazole, 4-[[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 157058-44-1P 226571-02-4P 226571-05-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREF (Preparation); RACT (Reactant or reagent)
(prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 226571-02-4 CAPLUS

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-
 (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS
 CN 1H-imidazole, 4-[[1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI)
 (CA INDEX NAME)



IT 628731-55-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; prepn. of 4-substituted imidazolethiones and imidazolones as
 agonists of .alpha.2B and .alpha.2C adrenergic receptors)

RN 628731-55-5 CAPLUS
 CN 1H-imidazole, 4-[[1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:950846 CAPLUS
 DOCUMENT NUMBER: 140:13072
 TITLE: Novel methods and compositions for alleviating pain
 INVENTOR(S): Gil, Daniel W.; Donello, John E.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099289	A2	20031204	WO 2003-US13057	20030423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003229088	A1	20031211	US 2002-153154	20020521
PRIORITY APPL. INFO.:			US 2002-153154	A 20020521
AB	The invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic .alpha.-adrenergic receptor in the absence of .alpha.-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic .alpha.-adrenergic receptor can be, for example, the .alpha.-2B receptor.			
IT	423773-40-4 423773-40-4B, stereoisomers			
RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
RN	423773-40-4 CAPLUS			
CN	1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)			




RN 423773-40-4 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 628730-35-8 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 628730-36-9 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:77587 CAPLUS
 DOCUMENT NUMBER: 138:122649
 TITLE: Preparation of imidazoles as selective agonists at .alpha.2B or .alpha.2C adrenergic receptors
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 329,752, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003023099	A1	20030130	US 2001-815362	20010321
US 2002156076	A1	20021024	US 2001-948001	20010906
WO 2002076950	A2	20021003	WO 2002-US8222	20020313
WO 2002076950	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GR, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1370533	A2	20031217	EP 2002-723489	20020313
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPL. INFO.:			US 1997-985347	B2 19971204
			US 1998-205597	B2 19981204
			US 1999-329752	B2 19990610
			US 2000-679919	A1 20001005
			US 2001-815362	A 20010321
			WO 2002-US8222	W 20020313


OTHER SOURCE(S): MARPAT 138:122649
 GI



AB Title compds. I [x = 1-2; R1 = H, halo, alk(en/yn)yl, etc.; R2-3 = H, halo, alk(en/yn)yl, etc.] which are selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors and useful for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated


L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
intraocular pressure with reduced cardiovascular or sedative side effects, are claimed. Also included are methods of making and using such compounds. Intrinsic activities towards .alpha.2A, .alpha.2B, .alpha.2C adrenergic receptors of approx.100 of the claimed compounds relative to brimonidine/oxymetazoline are tabulated.

IT 157058-47-4P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-44-1P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- 157058-52-1P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 157058-55-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- 226570-89-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride 226571-02-4P, 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- 226571-05-7P, 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- 226571-13-7P, 1H-Imidazole, 4-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-14-8P, 1H-Imidazole, 4-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-25-1P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- 226571-26-2P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- 226571-35-3P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- 226571-36-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride 226571-37-5P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-13-7 CAPLUS
CN 1H-Imidazole, 4-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 226571-14-8 CAPLUS
CN 1H-Imidazole, 4-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 226571-25-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 226571-02-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-36-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)



IT 226571-57-9P, 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (prepn. of imidazoles as selective agonists at .alpha.2b or
 .alpha.2b/.alpha.2c adrenergic receptors)
 RN 226571-57-9 CAPLUS
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[(1H-imidazol-4-ylmethyl)-7-methoxy-
 (9CI) (CA INDEX NAME)]



L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:754359 CAPLUS
 DOCUMENT NUMBER: 137:263032
 TITLE: Preparation of imidazoles as selective agonists at
 .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors
 Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt,
 Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk,
 Stephen A.; Gomez, Dario G.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076950	A2	20021003	WO 2002-US8222	20020313
WO 2002076950	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003023098	A1	20030130	US 2001-815362	20010321
EP 1370533	A2	20031217	EP 2002-723489	20020313
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPL. INFO.:			US 2001-815362	A 20010321
			US 1997-985347	B2 19971204
			US 1998-208597	B2 19981204
			US 1999-329752	B2 19990610
			WO 2002-US8222	W 20020313


OTHER SOURCE(S): MARPAT 137:263032
 GI



AB Comps. (shown as I), which are selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors and useful for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects, are claimed. Also included are methods of making and using such comps.


L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 In I, each x is independently 1 or 2; each R1 is independently H; halogen; Cl-4 alkyl; Cl-4 alkenyl; Cl-4 alkynyl; -COR4 where R4 is H, Cl-4 alkyl or Cl-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H; 1-2. Each R2 and each R3 are independently H; halogen; Cl-4 alkyl; Cl-4 alkenyl; Cl-4 alkynyl; -COR4 where R4 is H; Cl-4 alkyl or Cl-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H; 1-2; or an R2 and an R3 together condense to form a satd., partly satd., or unsatd. ring structure having the formula -[C(R6)p]q-Xs-[C(R6)p]r-Xt-[C(R6)p]u where each R6 is independently H; halogen; Cl-4 alkyl; Cl-4 alkenyl; Cl-4 alkynyl; -COR4 where R4 is H, Cl-4 alkyl or Cl-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl and oxo where each p is independently 1 or 2, q is 0-5, r is 0-5, u is 0-5. Each X is independently O, S, or N and s is 0 or 1; provided that q + r + u + s + t < 6. Y is O; S; N; -(C(R7)z)w, where each R7 is independently as previously defined for R1, each z is independently 1-2, and s is 1-3; -CH; -CH2; or Y1CH2, where Y1 is O, N, or S; and the dotted lines in I are optional double bonds, with the proviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsatd., and that if Y is O, N or S, the ring including Y contains at least one said double bond. Intrinsic activities towards .alpha.2A, .alpha.2B, .alpha.2C adrenergic receptors of .apprx.100 of the claimed comps. relative to brimonidine/oxymetazoline are tabulated. Although the methods of prepn. are not claimed, .apprx.100 example prepn. are included.

IT 157058-47-4P, 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-7-methoxy-
 R1: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
 RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-7-methoxy-
 (9CI) (CA INDEX NAME)]




IT 157058-44-1P, 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-7-methoxy-
 R1: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
 RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-7-methoxy-
 (9CI) (CA INDEX NAME)]


L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 1H-imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]-
 226571-36-4P, 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride 226571-37-5P,
 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-7-methyl-
 R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
 RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)]




RN 157058-52-1 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)]



RN 157058-55-4 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)]




RN 226570-89-4 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)]




● HCl

L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 226571-02-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS
 CN 1H-Imidazole, 4-[[[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-13-7 CAPLUS
 CN 1H-Imidazole, 4-[[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[[[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




IT 226571-57-9P, 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
 RN 226571-57-9 CAPLUS
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 226571-26-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
 CN 1H-Imidazole, 4-[[[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS
 CN 1H-Imidazole, 4-[[[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-37-5 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:576071 CAPLUS
 DOCUMENT NUMBER: 137:262610
 TITLE: Highly Enantioselective Reformatskii Reaction of Ketones: Chelation-Assisted Enantioface Discrimination
 AUTHOR(S): Ojida, Akio; Yamano, Toru; Taya, Naohiro; Tasaka, Akihiro
 CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan
 SOURCE: Organic Letters (2002), 4(18), 3051-3054
 CODEN: ORLEF7; ISSN: 1523-7069
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Highly enantioselective Reformatskii reaction of ketones was accomplished using cinchona alkaloids as chiral ligands. Chelation with the sp²-nitrogen adjacent to the reactive carbonyl center contributed to the enantioface discrimination for the high enantioselectivities.

IT 463304-62-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (chelation-assisted enantioface discrimination in asym. Reformatskii reactions)


RN 463304-63-4 CAPLUS
 CN 2-Oxazolidinone, 3-[(3S)-3-hydroxy-3-(1H-imidazol-4-yl)-3-(2-naphthalenyl)-1-oxopropyl]-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 463304-62-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (chelation-assisted enantioface discrimination in asym. Reformatskii reactions)
 RN 463304-62-3 CAPLUS
 CN 1,3-Propanediol, 1-(1H-imidazol-4-yl)-1-(2-naphthalenyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L6 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:391704 CAPLUS
DOCUMENT NUMBER: 136:401756
TITLE: Preparation of imidazole derivatives for treatment of prostate and breast cancer
INVENTOR(S): Tasaka, Akihiko; Matsunaga, Nobuyuki; Ojida, Akio; Kikawa, Masami
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040470	A1	20020523	WO 2001-JP10079	20011119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014320	A5	20020527	AU 2002-14320	20011119
JP 2002241377	A2	20020828	JP 2001-353524	20011119
EP 1344777	A1	20030917	EP 2001-982839	20011119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: JP 2000-353634 A 20001120 JP 2000-382056 A 20001215 WO 2001-JP10079 W 20011119				
OTHER SOURCE(S): MARPAT 136:401756				
GI				




AB The title compds., e.g. I [R is hydrogen or a protecting group; R1 is lower alkyl or cycloalkyl; and ring A is an optionally substituted 5- or 6-membered ring having an amide linkage], are prepd. I are steroid C17-20 lyase inhibitors and are useful in the treatment of prostate and breast cancer. The process for prepg. I is disclosed. 7-[1-Hydroxy-1-(1H-


L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benz[e]isoindol-3-one inhibited the biosynthesis of testosterone in rats. Formulations are given.
IT 430472-30-3P 430472-32-5P 430472-34-7P
430472-36-9P 430472-38-1P 430472-39-2P
430472-40-5P 430472-41-6P 430472-42-7P
430472-43-8P 430472-44-9P 430472-45-0P
430472-46-1P 430472-47-2P 430472-48-3P
430472-49-4P 430472-51-6P 430472-53-0P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazole derivs. for treatment of prostate and breast cancer)
RN 430472-30-3 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-32-5 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-34-7 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 2-ethyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-36-9 CAPLUS


L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 430472-38-1 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-39-2 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 2-cyclopropyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-40-5 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 430472-41-6 CAPLUS


L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3H-Benz[e]isoindol-3-one, 2-(dimethylamino)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-42-7 CAPLUS
 CN Benzo[f]phthalazin-4(1H)-one, 2,3-dihydro-8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-43-8 CAPLUS
 CN Benzo[f]phthalazin-4(3H)-one, 8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-44-9 CAPLUS
 CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 430472-45-0 CAPLUS
 CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 430472-46-1 CAPLUS
 CN Benzo[g]phthalazin-1(2H)-one, 3,4-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-47-2 CAPLUS
 CN Benzo[g]phthalazin-1(2H)-one, 7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-48-3 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 430472-49-4 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-51-8 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-, (-) (9CI) (CA INDEX NAME)

Rotation (-).



RN 430472-53-0 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-2-methyl- (9CI) (CA INDEX NAME)




L6 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:353314 CAPLUS
 DOCUMENT NUMBER: 136:365878
 TITLE: Methods and compositions for treatment of ocular neovascularization and neural injury
 INVENTOR(S): Burke, James A.; Lin, Ton; Wheeler, Larry A.; De Vries, Gerald W.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036162	A2	20020510	WO 2001-US46014	20011101
WO 2002036162	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GG, GW, ML, MR, NE, SN, TD, TG				
AU 2002030567	A5	20020515	AU 2002-30567	20011101
US 2002094998	A1	20020718	US 2001-998718	20011101
EP 1353692	A2	20031022	EP 2001-990804	20011101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003082183	A1	20030501	US 2002-20541	20020426
PRIORITY APPLN. INFO.: US 2000-244650P P 20001101				
WO 2001-US46014 W 20011101				
AB Methods and compos. for the treatment of ocular neovascularization (CNV) and macular degeneration are disclosed. The invention includes combining laser treatment with administration of a neuroprotectant. Seven pigmented rabbits were dosed with either 0.5 mL 0.2% brimonidine or saline administered in 1 eye of each rabbit. One hour later, the animals were treated with a 10-min i.v. infusion of 0.2 mg/kg verteporfin, then the same eye was irradiated 10 min later in the lower fundus with a 689-nm diode laser at 50 J/cm ² , 600 mW/cm ² and a spot size of 1.5 mm. Brimonidine reduced the increase in retinal thickness (subretinal cyst + retina) in the lesion produced by PDT.				
IT 226571-05-7, AGN 795 423773-40-4, AGN 960				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(methods and compos. for treatment of ocular neovascularization and neural injury)				
RN 226571-05-7 CAPLUS				
CN 1H-imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)				


L6 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:848687 CAPLUS
 DOCUMENT NUMBER: 136:146981
 TITLE: Investigations on inhibitors of human 17.alpha.-hydroxylase-17,20-lyase and their interactions with the enzyme. Molecular modelling of 17.alpha.-hydroxylase-17,20-lyase, part II
 AUTHOR(S): Schappach, A.; Holtje, H.-D.
 CORPORATE SOURCE: Department of Pharmacy, Institute of Pharmaceutical Chemistry, Heinrich Heine-University, Dusseldorf, Germany
 SOURCE: Pharmazie (2001), 56(11), 835-842
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB New methods in treatment of hormone-dependent diseases like prostate or breast cancer have become a major subject in medical and pharmaceutical research. Because of the direct correlation of cancer growth and hormone concn., inhibition of hormone biosynthesis presents a promising strategy in cancer therapy. The key enzyme in androgen biosynthesis is the 17.alpha.-hydroxylase-17,20-lyase a cytochrome P 450 system, which specifically converts gestagens to androgens. Because the 3D-structure of the enzyme is still unknown most recently a ligand-based design was used to gain deeper insights into protein structure and function. In this paper we present mol. modeling studies on compds. acting as competitive inhibitors of the human 17.alpha.-hydroxylase-17,20-lyase. The compds. developed by Hartmann et al. belong to two different structural classes and show a wide range of inhibitory potency. The physico-chem. properties of the mols. were investigated and compared by studying structural flexibility and by calco. mol. interactions fields. The superimposition of all inhibitors in a low energy conformation yielded in the common pharmacophore. In the second part of the paper individual inhibitors were docked into the active site of the enzyme model of CYP17 developed in our group. The dynamic behavior and stability of the protein-inhibitor-complexes was studied. The protein ligand interactions obsd. in course of the mol. dynamics simulations correspond well with the exptl. data.
 IT 157058-47-4
 RL: PRP (Properties)
 (mol. modeling of human 17.alpha.-hydroxylase-17,20-lyase with steroidal and non-steroidal inhibitors)
 RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 423773-40-4 CAPLUS
 CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:319877 CAPLUS
 DOCUMENT NUMBER: 134:340525
 TITLE: Process for producing optically active naphthalene derivative and optical resolver therefor
 INVENTOR(S): Aoki, Isao; Adachi, Mari; Kawada, Mitsuru; Yamano, Toru; Taya, Naohiro
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030763	A1	20010503	WO 2000-JP7282	20001019
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GG, GW, ML, MR, NE, SN, TD, TG				
AU 2000079499	A5	20010508	AU 2000-79499	20001019
EP 1227085	A1	20020731	EP 2000-969902	20001019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001187785	A2	20010710	JP 2000-320499	20001020
PRIORITY APPLN. INFO.: JP 1999-301570 A 19991022				
JP 1999-301576 A 19991022				
WO 2000-JP7282 W 20001019				
OTHER SOURCE(S): MARPAT 134:340525				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for producing an optically active isomer of a compd. represented by formula (I) which comprises: reacting a mixt. of naphthalene derivs. represented by formula I (wherein R represents a nitrogenous heterocyclic group; R1 represents hydrogen, a hydrocarbon group, or a mononuclear arom. heterocyclic group; R2 represents hydrogen or lower alkyl; symbol indicates the position of an asym. carbon atom; and R3 to R8 each represents hydrogen, a hydrocarbon group, hydroxy, etc., provided that R7 may be bonded to R6 or R8 to form a ring contg. an oxygen atom) with an optically active isomer of a 2-hydroxy-4-phenyl-1,3,2-dioxaphosphorinan-2-one or arom. ring-fused 2-hydroxy-1,3,2-dioxaphosphorinan-2-one compd. represented by formula (II) or (III), resp. (wherein ring A represents a benzene ring; R10 and R11 each represents hydrogen, a hydrocarbon group, etc., or R10 and R11 in combination represent alkylene; symbol indicates the position of an asym. carbon atom; and rings B and C each represents an arom. ring) to yield salts; sepp. the salts; and then isolating the target isomer. The optically active isomer produced has a steroid C17,20 lyase inhibitory activity and is useful as a preventive/remedy for tumors such as prostatism and mammary cancer. Also provided is a novel optical resolver II or III. Thus, 1.0 g (RS)-1-[(6,7-dimethoxynaphthalen-2-yl)-1-

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (1H-imidazol-4-yl)-2-methyl-1-propanol (IV) (prepn. given) and 822 mg
 (-)-8-hydroxy-7,9-dioxo-6-phenyl-8-phosphaspiro[4.5]decan-8-one (V) were
 dissolved in 21 mL ethanol with heating, stirred at room temp. for 6 h,
 and filtered to give 670 mg (-)-IV.V salt (99% de) in 74% yield which (665
 mg) was added to 150 mg 25% aq. NEH, 30 mL H₂O, and 20 mL AcOEt, and
 stirred at room temp. for 30 min. The org. layer was sepd. and concd. in
 vacuo to give 368 mg (-)-IV (99% de) in 74% yield.

IT 336102-55-7P 336102-62-6P


RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(process for producing optically active anticancer naphthalene deriv.
 and hydroxyphenyldioxaphosphorinane resolving agents)

RN 336102-55-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 336102-62-6 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




IT 336102-65-9 336102-70-6 336102-73-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (process for producing optically active anticancer naphthalene deriv.
 and hydroxyphenyldioxaphosphorinane resolving agents)

RN 336102-65-9 CAPLUS


CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-
 methylbutyl]-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-20-2 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-
 (9CI) (CA INDEX NAME)




RN 247173-40-6 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-41-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-54-2 CAPLUS


CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-
 naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-72-4 CAPLUS


CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX
 NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 336102-70-6 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-
 N-methyl- (9CI) (CA INDEX NAME)



RN 336102-73-9 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-
 methyl- (9CI) (CA INDEX NAME)



IT 247173-05-3P 247173-20-2P 247173-40-6P

247173-41-7P 247173-54-2P 247173-72-4P

247174-12-5P 336102-57-9P 336102-59-1P

336102-61-5P 336102-63-7P 336102-64-8P

336102-66-0P 336102-67-1P 336102-69-3P

336102-71-7P 336102-72-8P 336102-74-0P

336102-75-1P 336102-76-2P 337534-07-3P

337534-08-4P 337534-10-8P 337534-11-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(process for producing optically active anticancer naphthalene deriv.
 and hydroxyphenyldioxaphosphorinane resolving agents)

RN 247173-05-3 CAPLUS


CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247174-12-5 CAPLUS

CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA
 INDEX NAME)



RN 336102-57-9 CAPLUS


CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-, (.alpha.S)-, compd. with (-)-8-hydroxy-6-phenyl-7,9-dioxo-8-
 phosphaspiro[4.5]decane 8-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-56-8

CMF C13 H17 O4 P

Rotation (-).




CH 2

CRN 336102-55-7

CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



RN 336102-59-1 CAPLUS


CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-, (-)-, compd. with (4S)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-58-0
CMF C19 H22 N2 O2


Rotation (-).



CM 2

CRN 98674-91-0
CMF C11 H13 C12 O4 P

Absolute stereochemistry. Rotation (-).




RN 336102-61-5 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (+)-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-60-4
CMF C19 H21 N3 O2

Rotation (+).


L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 98674-82-9
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (+).




RN 336102-63-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (-)-4-(4-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-62-6
CMF C18 H20 N2 O2


Rotation (-).



CM 2

CRN 98674-89-6
CMF C11 H14 Cl O4 P

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Rotation (-).




RN 336102-64-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-62-6
CMF C18 H20 N2 O2


Rotation (-).



CM 2

CRN 98674-83-0
CMF C12 H17 O5 P


Absolute stereochemistry. Rotation (-).



RN 336102-66-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CRN 336102-65-9
CMF C20 H22 N2 O3



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 336102-67-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-65-9
CMF C20 H22 N2 O3




CM 2

CRN 98674-90-9
CMF C11 H13 C12 O4 P

Absolute stereochemistry. Rotation (+).


L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 336102-69-3 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-68-2
 CMF C19 H20 N2 O3



CM 2

CRN 98674-86-3
 CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).




RN 336102-71-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 2

CRN 98674-91-0
 CMF C11 H13 Cl2 O4 P


Absolute stereochemistry. Rotation (-).



RN 336102-74-0 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-73-9
 CMF C18 H19 N3 O2



CM 2

CRN 98674-90-9
 CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-75-1 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 1


CRN 336102-70-6
 CMF C20 H23 N3 O2



CM 2

CRN 98674-87-4
 CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 336102-72-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (-)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-70-6
 CMF C20 H23 N3 O2



L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 1


CRN 336102-73-9
 CMF C18 H19 N3 O2



CM 2

CRN 98674-87-4
 CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 336102-76-2 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-73-9
 CMF C18 H19 N3 O2




CM 2

CRN 98674-82-9

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (+).




RN 337534-07-3 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (11bR)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-55-7
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 39648-67-4
CMF C20 H13 O4 P




L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 98674-86-3
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-11-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-62-6
CMF C18 H20 N2 O2

Rotation (-).



CM 2

CRN 98674-86-3
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).


L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 337534-08-4 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 98674-80-7
CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-10-8 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 337534-09-5
CMF C18 H20 N2 O2

Rotation (-).

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 336103-01-6P 336103-02-7P 336103-04-9P
336103-06-1P 337534-12-0P

RL: SPN (Synthetic preparation): PREP (Preparation)
(process for producing optically active anticancer naphthalene deriv.
and hydroxyphenyldioxaphosphorinane resolving agents)


RN 336103-01-6 CAPLUS

CN Cyclohexanecarboxylic acid, 2-(aminocarbonyl)-, (1S,2R)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336103-00-5
CMF C8 H13 N O3

Absolute stereochemistry.



CM 2

CRN 247173-41-7
CMF C19 H22 N2 O3




RN 336103-02-7 CAPLUS
CN Benzenesulfonic acid, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-41-7
CMF C19 H22 N2 O3

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 17199-29-0
CMF C8 H8 O3

Absolute stereochemistry. Rotation (+).




RN 336103-04-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8
CMF C18 H19 N3 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI)
(CA INDEX NAME)


CM 1

CRN 247173-41-7
CMF C19 H22 N2 O3

CM 2


CRN 50573-41-6
CMF C8 H11 N O3 S

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 336103-06-1 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-05-0
CMF C20 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 337534-12-0 CAPLUS
CN Sulfamic acid, [(1S)-1-phenylethyl]-, compd. with .alpha.-(6,7-dimethoxy-2-


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:319876 CAPLUS
DOCUMENT NUMBER: 134:340505
TITLE: Preparation of imidazol-4-ylmethanols as steroid
C17-20 lyase inhibitors
INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXX82
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030762	A1	20010503	WO 2000-JP7283	20001019
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG			
AU 2000079500	A5	20010508	AU 2000-79500	20001019
EP 1222174	A1	20020717	EP 2000-969903	20001019
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2002080458	A2	20020319	JP 2000-327022	20001020
US 6649643	B1	20031118	US 2002-110599	20020412
PRIORITY APPL. INFO.:			JP 1999-301556 A	19991022
			JP 2000-189728 A	20000620
			WO 2000-JP7283	20001019
OTHER SOURCE(S):		MARFAT 134:340505		
GI				




L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

- AB Title compds. (I) {wherein R = H or a protecting group; R1 = (cyclo)alkyl; R3 and R5 = H, acyl, halo, or (un)substituted alkyl, hydroxyl, thio, or amino; R4 = (un)substituted aryl, heterocyclic, or carbamoyl; or R3 and R4 form a 5- or 6-membered O-contg. ring; or R4 and R5 form a 5- or 6-membered O-contg. ring; R6 = (halo)alkyl; n = 0-3; or salt thereof}, which have an inhibitory activity on steroid C17-20 lyase, were prepd. For example, Me 6-(1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl)-2-naphthoate (prepn. given) was deesterified using NaOH and MeOH in THF, converted to the amide using MeNH₂, and deprotected using pyridinium chloride to give the 1H-imidazolyl naphthalenemethanol 11. 11 inhibited steroid C17-20 lyase with IC₅₀ of 6.1 nM and showed inhibitory activity on testosterone biosynthesis (testosterone concn. of groups of rats receiving test compds. to control groups) of 4.5%. 11 are useful for the prevention and treatment of breast cancer or prostate cancer (no data).
- IT **247173-41-7P**, 1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **247173-54-2P**, N-[6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl]acetamide
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)
- RN **247173-41-7** CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




- RN **247173-54-2** CAPLUS
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




- IT **336103-03-8P**, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide **337520-97-5P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthonitrile **337521-57-0P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl-1-naphthamide **337521-60-5P**, 2-Hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide **337521-62-7P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide **337521-63-8P** **337521-94-5P**, (1H-Imidazol-4-yl)[naphtho[2,1-b]furan-7-yl]ketone **337521-99-0P**, (1H-Imidazol-4-yl)[naphtho[2,3-d][1,3]dioxol-6-yl]ketone


- L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)



- RN **337521-62-7** CAPLUS
 CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




- RN **337521-63-8** CAPLUS
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-[(methylamino)carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




- RN **337521-94-5** CAPLUS
 CN Methanone, 1H-imidazol-4-ynaphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)

- L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
337522-08-4P, (2,3-Dihydro-1H-benzo[f]chromen-8-yl)(1H-imidazol-4-yl)ketone **337522-19-7P**, (1,2-Dihydronaphtho[2,1-b]furan-7-yl)(1H-imidazol-4-yl)ketone **337522-26-6P**, (2,3-Dihydronaphtho[2,3-b]furan-6-yl)(1H-imidazol-4-yl)methanol **337522-27-7P**, (2,3-Dihydronaphtho[2,3-b]furan-6-yl)(1H-imidazol-4-yl)ketone **337522-28-0P**, 1-(2,3-Dihydronaphtho[2,3-b]furan-6-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **337534-08-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)
- RN **336103-03-8** CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



- RN **337520-97-5** CAPLUS
 CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




- RN **337521-57-0** CAPLUS
 CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)




- RN **337521-60-5** CAPLUS


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




- RN **337521-99-0** CAPLUS
 CN Methanone, 1H-imidazol-4-ynaphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)



- RN **337522-08-4** CAPLUS
 CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




- RN **337522-19-7** CAPLUS
 CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




- RN **337522-26-6** CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)- (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-27-7 CAPLUS
CN Methanone, [2,3-dihydronaphtho[2,3-b]furan-6-yl]-1H-imidazol-4-yl- (9CI)
(CA INDEX NAME)



RN 337522-28-8 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337534-08-4 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (-), compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).




CM 2

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 337522-94-8 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)




RN 337523-27-0 CAPLUS
CN Glycine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 337523-39-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-51-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-67-8 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(5-chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CRN 98674-80-7
CMF C11 H15 O4 P


Absolute stereochemistry. Rotation (-).



IT 337521-96-7P, 1-(1H-imidazol-4-yl)-1-[naphtho[2,3-d][1,3]dioxol-6-yl]-2-methyl-1-propanol 337522-45-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl-2-naphthamide 337522-94-8P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl-2-naphthamide 337523-27-0P, Ethyl [(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphtho[2,3-d][1,3]dioxol-6-yl)-1-(1H-imidazol-4-yl)ethyl]-N-methyl-2-naphthamide 337523-39-4P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl-2-naphthamide 337523-51-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl-2-naphthamide 337523-67-8P, 1-[5-Chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)


RN 337521-96-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-naphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)




RN 337522-45-9 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl- (9CI) (CA INDEX NAME)




L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 336102-55-7P, (S)-(-)-1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 336102-68-2P, Methyl 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoate 336102-70-6P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-2-naphthamide 336102-73-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337521-66-1P, 1-(1H-imidazol-4-yl)-2-methyl-1-(6-phenyl-2-naphthyl)-1-propanol 337521-68-3P, 1-[6-(2-Furyl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337521-70-7P, 1-(1H-imidazol-4-yl)-2-methyl-1-(6-(2-thienyl)-2-naphthyl)-1-propanol 337521-74-1P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-propanol 337521-77-4P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3,4-tetrazol-5-yl)-2-naphthyl]-1-propanol 337521-79-6P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-pyrazol-4-yl)-2-naphthyl]-1-propanol 337521-81-0P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-propanol 337521-84-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337521-86-5P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy-2-naphthamide 337521-89-8P, 1-(1H-imidazol-4-yl)-1-(naphtho[2,1-b]furan-7-yl)-2-methyl-1-propanol 337521-95-6P, 1-(1,2-Dihydro-1H-benzofuran-7-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-00-6P, 1-(2,3-Dihydro-1H-benzofuran-8-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-09-5P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)ethanol 337522-10-8P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)propanol 337522-12-0P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-ethanol 337522-21-1P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-propanol 337522-31-3P, 337522-33-5P, (-)-N-[6-(1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)naphthalen-2-yl]acetamide 337522-40-4P, 337522-41-5P, N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-49-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropyl-2-naphthamide 337522-53-9P, N-Butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-57-3P, N-Cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-61-9P, N-Cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-64-2P, N-Cyclopentylmethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-67-5P, N-Cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-69-7P, N-Cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-72-2P, N-Cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-74-4P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-77-7P, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-79-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl-2-naphthamide 337522-83-5P, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337522-88-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 methylpropyl]-N,1-dimethyl-2-naphthamide **337522-99-3P**,
 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl-2-naphthamide
337523-03-2P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-
 N,N-dimethyl-2-naphthamide **337523-06-5P**, 1-(1H-imidazol-4-yl)-2-
 methyl-1-[6-(1-pyrrolidinylcarbonyl)-2-naphthyl]-1-propanol
337523-11-2P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-
 (1,3-thiazol-2-yl)-2-naphthamide **337523-16-7P**,
 N-Ethoxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide
337523-20-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-
 isopropoxy-2-naphthamide **337523-24-7P**, N-(2-Hydroxyethyl)-6-[1-
 hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide
337523-32-7P **337523-36-1P** **337523-47-4P**
337523-61-2P, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-
 methylpropyl]-N-methyl-2-naphthamide **337523-63-4P**,
 (S)-(-)-N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-
 naphthamide **337523-65-6P**, (S)-(-)-N-Cyclopropyl-6-[1-hydroxy-1-
 (1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337523-76-9P**,
 1-[5-Chloro-6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-
 1-propanol **337523-82-7P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-
 methylbutyl]-2-naphthamide **337523-86-1P**, 1-(1H-imidazol-4-yl)-3-
 methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-butanol
337523-94-1P, 1-(1H-imidazol-4-yl)-3-methyl-1-[6-(1,3-oxazol-5-yl)-
 2-naphthyl]-1-butanol **337524-00-2P**, 1-[6-(4,4-Dimethyl-4,5-
 dihydro-1,3-oxazol-2-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-
 propanol **337524-05-7P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BTL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase
 inhibitors for treatment of breast and prostate cancer)
 RN 336102-55-7 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 336102-68-2 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-
 methylpropyl]-, methyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337521-70-7 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(2-thienyl)-2-
 naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-74-1 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-1,2,3-
 triazol-4-yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-77-4 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-tetrazol-5-
 yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-79-6 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-pyrazol-4-
 yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 336102-70-6 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-
 N-methyl- (9CI) (CA INDEX NAME)



RN 336102-73-9 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-
 methyl- (9CI) (CA INDEX NAME)




RN 337521-66-1 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-phenyl-2-
 naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-68-3 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(2-furanyl)-2-naphthalenyl)-.alpha.-(1-
 methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 337521-81-0 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(5-oxazolyl)-2-
 naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-84-3 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-
 methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-86-5 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-
 methylpropyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 337521-89-8 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1,2-dihydronaphtho[2,1-
 b]furan-7-yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-95-6 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-
 .alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337522-00-6 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337522-09-5 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 337522-10-8 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-ethyl- (9CI) (CA INDEX NAME)




RN 337522-12-0 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 337522-33-5 CAPLUS
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 337522-40-4 CAPLUS
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 337522-33-5
 CMF C19 H21 N3 O2


Rotation (-).



CM 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 337522-41-5 CAPLUS
 CN 2-Naphthalenecarboxamide, N-ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-21-1 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-ethyl- (9CI) (CA INDEX NAME)




RN 337522-31-3 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
 CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).




CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.




L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337522-49-3 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337522-53-9 CAPLUS
 CN 2-Naphthalenecarboxamide, N-butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-57-3 CAPLUS
 CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-61-9 CAPLUS
 CN 2-Naphthalenecarboxamide, N-cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337522-64-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(cyclopropylmethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-67-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-(cyclopentylmethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-69-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(cyclohexylmethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-72-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(cycloheptylmethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337522-88-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl- (9CI) (CA INDEX NAME)



RN 337522-99-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 337523-03-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337523-06-5 CAPLUS
CN Pyrrolidine, 1-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337522-74-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-77-7 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-79-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 337522-83-5 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337523-11-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 337523-16-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethoxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337523-20-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 337523-24-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(2-hydroxyethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337523-32-7 CAPLUS
CN L-Alanine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-36-1 CAPLUS
CN D-Alanine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-47-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-(cyclopropylhydroxy-1H-imidazol-4-ylmethyl)-N-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337523-61-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 337523-63-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethyl-6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 337523-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 337523-76-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(5-chloro-6-(5-oxazolyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337523-82-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]- (9CI) (CA INDEX NAME)




RN 337523-86-1 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-[6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337523-94-1 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337524-00-2 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337524-05-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8
CMF C18 H19 N3 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ACCESSION NUMBER: 2001:12424 CAPLUS
 DOCUMENT NUMBER: 134:86245
 TITLE: Preparation of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors.
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000586	A1	20010104	WO 2000-US15795	20000608
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1104407	A1	20010606	EP 2000-939699	20000608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 2002156076	A1	20021024	US 2001-948001	20010906
PRIORITY APPLN. INFO.:			US 1999-329752	A 19990610
			US 1997-985347	B2 19971204
			US 1998-205597	B2 19981204
			WO 2000-US15795	W 20000608
			US 2000-679919	A1 20001005

OTHER SOURCE(S): MARPAT 134:86245
 GI




AB Title compds. [I: dotted lines = optional double bonds; R = H, alkyl; X = S, CHR1; R1 = H, alkyl, null; Y = O, N, S, [C(R)]nly, CH2CH, YICH2; Y = 1-3; n = 1, 2; R2 = H, alkyl, halo, OH, alkoxy, alkenyl, acyl, alkynyl, etc.; R3, R4 = H, alkyl, halo, alkenyl, acyl, alkynyl, etc.; R3R4 = atoms to form (unsatd.) (heterocyclic) ring], were prepd. Thus, 1-(dimethylsulfamoyl)imidazole in THF at -78.degree. was treated with BuLi and tert-butylidimethylsilyl chloride followed by warming to room temp., stirring overnight, cooled to -20.degree., and treatment with BuLi and

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




• HCl


RN 226571-02-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




IT 157058-44-1 157058-52-1 226571-13-7
 226571-14-8 226571-25-1 226571-26-2
 226571-35-3 226571-36-4 226571-37-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
 RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 3-thiophenecarboxaldehyde followed by warming to room temp. and stirring overnight to give 2-(tert-butylidimethylsilyl)-5-(hydroxythiophen-2-ylmethyl)imidazole-1-sulfonic acid dimethylamide. This was treated sequentially with Bu4NF, Et3SiH/CF3CO2H/CH2Cl2, and aq. HCl to give 4(5)-thiophen-3-ylmethyl-1H-imidazole. Tested 1 as eyedrops at 0.03-1% reduced intraocular pressure in cynomolgus monkeys by 12.4-33% and showed no sedative activity.
 IT 157058-47-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
 RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-55-4P 226570-89-4P 226571-02-4P
 226571-05-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
 RN 157058-55-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226570-89-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 226571-13-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-26-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)

C[C@H]1C(C)[C@H](Cc2c[nH]cn2)C3=CC=CC=C13Cc1ccc2c(c1)CC(C2)CC3=CN=CN=C3

● HCL





Cc1ccc2c(c1)C(=O)C(C2)Cc3c[nH]c3

L6 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN


DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PRIORITY APPLN. INFO.: JP 1999-175070 A 19990622
WO 2000-1P4036 W 20000621

OTHER SOURCE(S): CASREACT 134:56671; MARPAT 134:56671
G1




L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
(SCI) (CA INDEX NAME)



16 ANSWER 12 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
group and R1, R2, R3, R4, R5, R6, and R7 are each hydrogen, optionally
substituted hydrocarbyl, OH, SH, NH2, acyl, halogeno, or the like)
comprises addn. reaction of 4-cyanimidazole (II); the ring A is same as
above) with R-M1 (R is same as above; M1 = alkali metal, Mg-Y1; Y1 =
halo) to give 4-acylimidazole (III); R and ring A are same as above),
followed by addn. reaction of III with naphthalene alkali metals (IV; R1 -
R7 are = same as above; M2 is alkali metal, Mg-Y2; Y2 is halo). This
process is reduced in the no. of steps, attains a high yield, and
disposes with the use of a heavy metal compound. The compounds exhibit a
steroid C17-C20 lyase inhibitory activity (no data). Thus, a soln. of
42.7 g 4-cyanimidazole in 500 mL THF was added dropwise to a 1.1 M soln.
of isopropylmagnesium bromide in THF (1.4 L) over a period of 30 min,
stirred at 15-25.degree., treated dropwise with 100 g Et2SO4, stirred for
30 min, neutralized to pH 8 with 30 g NaOH, and extd. with EtOAc (300 L
.times.2), to give 824 1-(1H-imidazole-4-yl)-2-methyl-1-propanone (V).
2-Bromo-6-methoxynaphthalene (5.0 g, 0.02 mol) was added dropwise to a
soln. of 0.55 g (0.02 mol) of NaH in 50 mL THF at 50.degree. and stirred at 15-25.degree.
for 1.5 h, followed by adding dropwise a soln. of 1 g V in THF, and the
resulting mixt. was stirred at 15-25.degree. for 8 h to give, after
workup, 841 1-(1H-imidazole-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-
methylpropanol.

IT 247173-05-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 4-alkanyliimidazole derivs. and .alpha.-(2-naphthyl)-.alpha.-(1H-imidazolyl)alkanol derivs. by addn. reaction of cyanoimidazoles with alkylmagnesium bromides followed by naphthylmagnesium bromide)

with alkylmagnesium bromides followed by naphthylmagnesium bromide)
RN 247173-05-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB An industrially advantageous process for the prepn. of compds. of general formula (I; wherein the ring A is an optionally substituted imidazole ring; R is an optionally substituted hydrocarbon group or a heterocyclic

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ACCESSION NUMBER: 1999:691084 CAPLUS
 DOCUMENT NUMBER: 131:299449
 TITLE: Preparation of azolymethylnaphthalenes and related compounds as steroid C17,20-lyase inhibitors.
 INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 131 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954309	A1	19991028	WO 1999-JP2143	19990422
W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2328973	AA	19991028	CA 1999-2328973	19990422
AU 9935346	A1	19991108	AU 1999-35346	19990422
JP 2000007658	A2	20000111	JP 1999-114398	19990422
EP 1073640	A1	20010207	EP 1999-917102	19990422
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
US 6573289	B1	20030603	US 2000-673591	20001018
US 2003236274	A1	20031225	US 2003-443379	20030522
PRIORITY APPLN. INFO.:			JP 1998-113801	A 19980423
			WO 1999-JP2143	W 19990422
			US 2000-673591	A3 20001018

OTHER SOURCE(S): MARPAT 131:299449
 GI



AB Title compds. [I: A1 = (substituted) imidazolyl, thiazolyl, oxazolyl, pyridyl; R11 = H, (substituted) hydrocarbyl, monocyclic heteroaryl; R21 = H, (substituted) alkyl; R3-R9 = H, (substituted) hydrocarbyl, OH, SH, amino, acyl, halo; R21 = (substituted) alkyl], and salts or prodrugs thereof, were prepd. Thus, 2-bromo-6-methoxynaphthalene in THF at -78.degree. was treated with BuLi and then with 4-formyl-1-trityl-1H-


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 247173-07-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 247173-09-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(cyclopropyl)-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 247173-08-6
 CMF C18 H18 N2 O2



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 247173-11-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1,1-dimethylethyl)-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-10-0
 CMF C19 H22 N2 O2




L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 imidazole to give (6-methoxynaphthalen-2-yl) (1-trityl-1H-imidazol-4-yl)methanol. The product was refluxed with MnO2 in CHCl3 to give the ketone, which was deprotected with HCOOH in THF to give (1H-imidazol-4-yl) (6-methoxynaphthalen-2-yl) ketone. The latter in THF at -10.degree. was treated with Me2CHMgBr in THF to give 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methyl-1-propanol. This inhibited rat steroid C17,20-lyase with IC50 = 33 nM. 1 drug formulations are given.


IT 247173-05-3P 247173-06-4P 247173-07-5P
 247173-09-7P 247173-11-1P 247173-12-2P
 247173-13-3P 247173-14-4P 247173-17-7P
 247173-18-8P 247173-19-9P 247173-20-2P
 247173-21-3P 247173-22-4P 247173-24-6P
 247173-25-7P 247173-26-8P 247173-27-9P
 247173-28-0P 247173-29-1P 247173-30-4P
 247173-31-5P 247173-32-6P 247173-33-7P
 247173-34-8P 247173-35-9P 247173-36-0P
 247173-37-1P 247173-38-2P 247173-39-3P
 247173-40-6P 247173-41-7P 247173-42-8P
 247173-43-9P 247173-44-0P 247173-45-1P
 247173-46-2P 247173-47-3P 247173-48-4P
 247173-49-5P 247173-50-8P 247173-51-9P
 247173-52-0P 247173-53-1P 247173-54-2P
 247173-55-3P 247173-56-4P 247173-57-5P
 247173-58-6P 247173-59-7P 247173-60-0P
 247173-61-1P 247173-62-2P 247173-63-3P
 247173-64-4P 247173-65-5P 247173-66-6P
 247173-68-8P 247173-69-9P

RI: FAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of azolymethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)

RN 247173-05-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-06-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-methyl- (9CI) (CA INDEX NAME)




L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.




RN 247173-12-2 CAPLUS
 CN 3-Pyridinemethanol, .alpha.-(1H-imidazol-4-yl)-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-13-3 CAPLUS
 CN 4-Pyridinemethanol, .alpha.-(1H-imidazol-4-yl)-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-14-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 247173-17-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(5-fluoro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-18-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-19-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 247173-20-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)




RN 247173-21-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-cyclopentyl- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-27-9 CAPLUS
CN 1H-Imidazole, 4-[(6-methoxy-2-naphthalenyl)(1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 247173-28-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-29-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-30-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-[1-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl)-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-22-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-24-6 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 247173-25-7 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 247173-26-8 CAPLUS
CN 1H-Imidazole, 4-[methoxy(6-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-31-5 CAPLUS
CN 1,6-Naphthalenedimethanol, .alpha.6-1H-imidazol-4-yl-2-methoxy-.alpha.1-methyl-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-32-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-33-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-34-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-35-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, [[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]oxy]methyl ester (9CI) (CA INDEX NAME)



RN 247173-36-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-(1-methylethoxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-37-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-propoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-38-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-43-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5,6-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-44-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-7-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-45-1 CAPLUS
CN 1,6-Naphthalenedimethanol, .alpha.6-1H-imidazol-4-yl-2-methoxy-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-46-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5-(methoxymethyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-39-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-(2-methoxyethoxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-41-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-42-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-47-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-48-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethenyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-49-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-bromo-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-50-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-(fluoromethoxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-51-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5,7-dimethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-52-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-53-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS
CN Acetamido, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-59-7 CAPLUS
CN Ethanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-60-0 CAPLUS
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-61-1 CAPLUS
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 247173-62-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-55-3 CAPLUS
CN Urea, N'-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 247173-56-4 CAPLUS
CN Urea, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 247173-57-5 CAPLUS
CN Methanesulfonamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-58-6 CAPLUS
CN 2,6-Naphthalenedimethanol, .alpha.-(1H-imidazol-4-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 247173-63-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-methyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-64-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethynyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-65-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(methylthio)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-66-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-1-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-68-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-69-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




IT 247174-67-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azolymethylnaphthalenes and related compds. as steroid
C17,20-lyase inhibitors)
RN 247174-67-0 CAPLUS
CN Methanone, (5-fluoro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI)
(CA INDEX NAME)




IT 247173-72-4P 247173-89-3P 247173-95-1P
247174-00-1P 247174-01-2P 247174-05-6P
247174-12-5P 247174-17-0P 247174-24-9P
247174-25-0P 247174-26-1P 247174-35-2P
247174-36-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of azolymethylnaphthalenes and related compds. as steroid
C17,20-lyase inhibitors)
RN 247173-72-4 CAPLUS
CN Methanone, 1H-imidazol-4-yl (6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX
NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247174-05-6 CAPLUS
CN Methanone, 1H-imidazol-4-yl (6-methoxy-5-(1-methylethenyl)-2-naphthalenyl)-
(9CI) (CA INDEX NAME)




RN 247174-12-5 CAPLUS
CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA
INDEX NAME)




RN 247174-17-0 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247174-24-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247173-89-3 CAPLUS
CN Methanone, 1H-imidazol-4-yl (7-methoxy-6-(phenylmethoxy)-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-95-1 CAPLUS
CN Methanone, (5-chloro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI)
(CA INDEX NAME)




RN 247174-00-1 CAPLUS
CN Methanone, [5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-6-methoxy-2-naphthalenyl]-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 247174-01-2 CAPLUS
CN Methanone, 1H-imidazol-4-yl (6-methoxy-5-(1-methylethenyl)-2-naphthalenyl)- (9CI) (CA
INDEX NAME)


L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 247174-25-0 CAPLUS
CN Methanone, 1H-imidazol-4-yl (7-methoxy-6-(phenylmethoxy)-2-naphthalenyl)-
(9CI) (CA INDEX NAME)



RN 247174-35-2 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247174-36-3 CAPLUS
CN Methanone, (6-methoxy-5,7-dimethyl-2-naphthalenyl)-1H-imidazol-4-yl- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:375530 CAPLUS
 DOCUMENT NUMBER: 131:19013
 TITLE: Preparation of .alpha.2B and .alpha.2C adrenoceptor agonists
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 121 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928300	A1	19990610	WO 1998-0525669	19981203
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NI, SN, TD, TG			
CA 2312334	AA	19990610	CA 1998-2312334	19981203
AU 9918025	A1	19990616	AU 1999-18025	19981203
AU 744798	B2	20020307		
EP 1036065	A1	20000920	EP 1998-962883	19981203
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
BR 9813381	A	20001003	BR 1998-13381	19981203
JP 2001524542	T2	20011204	JP 2000-523194	19981203
NZ 504667	A	20030328	NZ 1998-504667	19981203
NO 2000002773	A	20000802	NO 2000-2773	20000530
US 2002156076	A1	20021024	US 2001-948001	20010906

PRIORITY APPLN. INFO.:
 US 1997-985347 A 19971204
 WO 1998-0525669 W 19981203
 US 1998-205597 B2 19981204
 US 1999-329752 B3 19990610
 US 2000-675919 A1 20001005


OTHER SOURCE(S):
 MARPAT 131:19013

AB Title compds. of diverse structural type were prepd. Thus, 7-methoxy-1-tetralone was condensed with 1-dimethylsulfamoyl-2-tert-butylidimethylsilyl-5-imidazolecarboxaldehyde (prepn. given) and the product converted in 3 steps to 4(5)-(7-methoxy-1,2,3,4-tetrahydronaphth-2-ylmethyl)-1H-imidazole. Data for biol. activity of title compds. were given.


IT 157058-44-1P 157058-47-4P 157058-52-1P
 157058-55-4P 226570-89-4P 226571-02-4P
 226571-05-7P 226571-13-7P 226571-14-8P
 226571-25-1P 226571-26-2P 226571-35-3P
 226571-36-4P 226571-37-5P 226571-43-3P
 226571-55-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)
 RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 157058-55-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226570-89-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 226571-02-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-13-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-26-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 226571-35-3 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-36-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 226571-37-5 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)



RN 226571-43-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-55-7 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 226571-05-7
 CMF C14 H20 N2




L6 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:244636 CAPLUS
 DOCUMENT NUMBER: 130:252360
 TITLE: Preparation of dihydronaphthalene compounds
 INVENTOR(S): Hartmann, Rolf Wolfgang; Wachall, Bertil; Yoshihama, Makoto; Nakakoshi, Masamichi; Nomoto, Shin; Ikeda, Yoshihazu
 PATENT ASSIGNEE(S): Yuki Jirushi Nyugyo Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918075	A1	19990415	WO 1998-JP4426	19981001
W: AU, CA, CN, FI, HU, IL, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9808954	A	19990412	ZA 1998-8954	19981001
AU 9892810	A1	19990427	AU 1998-92810	19981001
AU 743405	B2	20020124		
EP 1028110	A1	20000816	EP 1998-945556	19981001
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
NZ 501822	A	20011221	NZ 1998-501822	19981001
RU 2203890	C2	20030510	RU 1999-127323	19981001
CN 1117732	B	20030813	CN 1998-808436	19981001
FI 200000207	A	20000201	FI 2000-207	20000201
NO 2000001289	A	20000310	NO 2000-1289	20000310
US 2002032211	A1	20020314	US 2001-866179	20010525
US 6559157	B2	20030506		
PRIORITY APPLN. INFO.:			JP 1997-284263	A 19971002
			WO 1998-JP4426	W 19981001
			US 1999-424126	B1 19991117

OTHER SOURCE(S): MARPAT 130:252360
 GI



I

AB Dihydronaphthalene compds. I (R1 = H, OH, alkyloxy; R2 = alkyl, aralkyl, Ph; R3 = alkyl, Ph, pyridyl, imidazolyl), useful as 17.alpha.-hydroxylase/C17-20-lyase inhibitors, thromboxane A2 synthesis inhibitors, and aromatase inhibitors, were prepd. I (R1 = H, R2 = Me, R3 = 3-pyridyl) showed 17.alpha.-hydroxylase/C17-20-lyase and aromatase inhibitor activity.


IT 157058-45-2P 157058-46-3P 157058-47-4P
 221651-52-1P 221651-54-3P 221651-56-5P
 221651-61-2P 221651-64-5P
 RL: IMP (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of dihydronaphthalenes)

L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




IT 226571-57-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)
 RN 226571-57-9 CAPLUS
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 157058-45-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 221651-52-1 CAPLUS
 CN 1(2H)-Naphthalenone, 5-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 221651-54-3 CAPLUS
 CN 1(2H)-Naphthalenone, 6-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 221651-56-5 CAPLUS
CN 1(2H)-Naphthalenone, 7-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 221651-61-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-propoxy- (9CI) (CA INDEX NAME)




RN 221651-64-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-(2-methylpropoxy)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)
RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-45-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 157058-46-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



IT 157058-52-1P 157058-53-2P 157058-55-4P
178880-06-3P

L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 1996:358249 CAPLUS
DOCUMENT NUMBER: 125:75343
TITLE: Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 aro, P450 17 and P450 TxA2
AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber, Dorothea; Waechter, Gerald A.; Gruen, Gertrud L.; Sergejew, Tom F.
CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ. Saarlandes, Saarbruecken, D-66041, Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(5), 251-261
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing of OCH₃ substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-spacer between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 aro (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 TxA₂ (citratated human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 scc (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compds. were examd. in Sprague Dawley rats regarding P 450 TxA₂ inhibition, redn. of plasma testosterone concn., antiuterotrophic activity (inhibition of the uterotrophic activity of androstenedione), redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent new azole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 aro and/or P 450 17 were found: 7-OCH₃-2-(imidazol-4-ylmethylene)-1-tetralone (I) and 7-OCH₃-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 aro in vitro know so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH₃ deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 TxA₂: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 TxA₂, whereas 7-OCH₃-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH₃-2-imidazol-1-yl-3,4-dihydronaphthalene addnl. show strong inhibition of P 450 aro and P 450 17. Structure-activity relations are discussed. Regarding the other steroidogenic P 450 enzymes as well as corticosterone formation, the compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concns. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 aro fadrozole. The compds. show activity in the aforementioned in vivo tests.
IT 157058-44-1P 157058-45-2P 157058-46-3P
157058-47-4P


RI: BAC (Biological activity or effector, except adverse); BSU (Biological

L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178880-06-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 157058-54-3
CMF C15 H18 N2 O

L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

L6 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:827732 CAPLUS
DOCUMENT NUMBER: 124:202093
TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV. [Erratum to document cited in CA123:198689]
AUTHOR(S): Hatanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Tokumoto, H.; Kondo, K.
CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(18), 2179
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English


AB The errors were not reflected in the abstr. or the index entries.

IT 150559-29-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(PGI2 agonist activity of (Erratum))

RN 150559-29-8 CAPLUS

CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:97011 CAPLUS
DOCUMENT NUMBER: 124:260928
TITLE: Novel nonprostanoid prostacyclin (PGI2) mimetics with heterocyclic moiety
AUTHOR(S): Nagao, Yuuki; Takahashi, Kanji; Torisu, Kazuhiko; Kondo, Kigen; Hatanaka, Nobuyuki
CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
SOURCE: Heterocycles (1996), 42(2), 517-23
CODEN: HETCYM; ISSN: 0365-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Structural modification of [[6-[[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(2-benzhydryloxyimino)pentyl]-1,2,3,4-tetrahydro-5-naphthyl]oxy]acetic acid], previously identified as a PGI2 agonist without a PG skeleton, was examd. Such analogs were for example, [[6-[[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid or [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid. Conversion of the oxime moiety in [[6-[[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid to a pyrazole led to [[6-[[4-(diphenylmethyl)-1H-pyrazol-1-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(4-benzhydrylpyrazolyl)methyl]-1,2,3,4-tetrahydro-5-naphthyl]oxy]acetic acid] which strongly inhibited ADP-induced aggregation of human platelets in vitro.


IT 150559-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of [[[[[phenylmethoxy]imino]alkyl]naphthalenyl]oxy]acetate analogs as nonprostanoid prostacyclin mimetics)

RN 150559-29-8 CAPLUS

CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:612212 CAPLUS
DOCUMENT NUMBER: 123:198691
TITLE: Medetomidine analogs as .alpha.-adrenergic agonists
AUTHOR(S): Amemiya, Yoshiya; Hus, Fulian; Shams, Gamal; Feller, Dennis R.; Venkataraman, R. V.; Patil, Popat N.; Miller, Duane D.
CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 403-10
CODEN: EJPSRZ; ISSN: 0301-5068
PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:198691


AB Recently, it has been reported that medetomidine is a new 4-substituted imidazole analog possessing selective and potent .alpha.2-adrenergic properties. It has been shown that it reduces blood pressure, heart rate and saliva secretion. At the present time is sedative and hypotensive effects seem to be manifest in the same dose range. We have initiated a program to see if it is possible to sep. these activities with analogs of medetomidine. The initial studies have been directed at procedures for the conversion of the imidazolines, a common structure of .alpha.-adrenergic drugs, to the corresponding imidazoles. It was found that 2-substituted and 2,4-disubstituted imidazolines can easily be converted into imidazoles using 10% Pd/C in refluxing toluene, while in some instances there are some difficulties with the conversion of 4-substituted imidazolines to the imidazoles. The synthesis of 1- or 2-(2- or 4-imidazolylmethyl)naphthalene analogs of medetomidine are also described.

IT 137967-88-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of 4-substituted imidazoles)

RN 137967-88-5 CAPLUS

CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:612188 CAPLUS
 DOCUMENT NUMBER: 123:111932
 TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs of .alpha.- and .beta.-naphthalene
 AUTHOR(S): Amemiya, Yoshiya; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl
 CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 91-112
 CODEN: EJPSRZ; ISSN: 0301-5068
 PUBLISHER: National Information and Documentation Centre
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Seven analogs of medetomidine and naphazoline were synthesized and evaluated for their .alpha.-1- (aorta) and .alpha.-2- (platelet) activities. The analogs were composed of 2- and 4-substituted imidazoles and imidazolines attached through a methylene bridge to either an .alpha.- or .beta.-naphthalene ring system. In general the .alpha.-naphthalene analogs were found to be the most potent inhibitors of platelet aggregation. .alpha.-Naphthalene analogs were partial agonists while the .beta.-naphthalene analogs were antagonists in .alpha.-1-adrenergic system (aorta).

IT 137967-82-9P 166034-65-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and adrenergic activities of medetomidine and naphazoline analogs)
 RN 137967-82-9 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 166034-65-7 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 137967-88-5
 CMF C15 H14 N2

L6 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:598392 CAPLUS
 DOCUMENT NUMBER: 123:198689
 TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV
 AUTHOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Nagao, Yuuki; Torisu, Kazuhiko; Tokumoto, Hidekado; Kondo, Kigen
 CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(10), 1083-6
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

GI




I


AB The synthesis and biol. evaluation of a novel series of di- or tetrahydronaphthalen-5-oxyacetic acid derivs. with a 4-benzhydrylpyrazolyl group is described. Among these compds., I has been identified as a highly potent PGI2 agonist with an exceptionally long in vivo duration of action.

IT 150559-29-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (PGI2 agonist activity of)

RN 150559-29-8 CAPLUS
 CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2

CRN 144-62-7
 CMF C2 H2 O4



IT 137967-88-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and adrenergic activities of medetomidine and naphazoline analogs)
 RN 137967-88-5 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 1995:513524 CAPLUS
 DOCUMENT NUMBER: 122:265379
 TITLE: Preparation of (cyanobenzyl)azole derivatives as aromatase inhibitors
 INVENTOR(S): Shibata, Tomoyuki; Sugimura, Yukio; Tanzawa, Kazuhiko; Takahashi, Masasaki; Kobayashi, Tomowo; Mitsuhashi, Yoshihiro
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9408973	A1	19940428	WO 1993-JP1509	19931020
W: AU, CA, CZ, FI, HU, KR, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 5352855	A1	19940509	AU 1993-52855	19931020
JP 06263742	A2	19940920	JP 1993-261438	19931020
PRIORITY APPLN. INFO.:			JP 1992-283177	19921021
			WO 1993-JP1509	19931020
OTHER SOURCE(S):			MARFAT 122:265379	


GI



I




II




III

AB The title compds. (I; R1 = imidazolyl, triazolyl or tetrazolyl each of which may be substituted by Me and/or Et; R2 = naphthyl, phenanthryl or anthryl each of which may be substituted by substituent(s) selected from C1-4 alkyl, C1-4 alkoxy, C1-6 acyloxy, arom. acyloxy, OH, trialkyl, C1-4 acylamino, alkoxyalkoxy, alkoxyacyloxy, and trialkylsilyloxy; R3 = H, Me, cyano), useful for the treatment of breast cancer, are prepd. Thus, 2-bromo-6-methoxynaphthalene was treated with BuLi in hexane and THF at

L6 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 -78.degree. followed reaction with a soln. of p-cyanobenzaldehyde in THF at -78.degree. gave p-cyano- α -(6-methoxynaphthalen-2-yl)benzyl alc. which was stirred with SOCl₂ in CH₂Cl₂ at room temp. for 1 h to give p-cyano- α -(6-methoxynaphthalen-2-yl)benzyl chloride. The latter chloride was dissolved in MeCN and refluxed with imidazole overnight to give, after silica gel chromatog. and acidification with HCl, title compd. (II.HCl) which in vitro showed IC₅₀ of 3.7 nM against aromatase. Hard capsule, tablet, injection and suspension formulations contg. (p-cyanobenzyl)tetrazole deriv. (III.HCl) were described.
 IT 162573-42-4P 162573-46-8P 162573-58-2P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
 (prepn. of (cyanobenzyl)azole deriv. as aromatase inhibitor and anticancer agent for breast cancer)
 RN 162573-42-4 CAPLUS
 CN Benzonitrile, 4-((1H-imidazol-4-yl)-2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 162573-46-8 CAPLUS
 CN Benzonitrile, 4-((1H-imidazol-4-yl)-9-phenanthrenylmethyl)- (9CI) (CA INDEX NAME)



RN 162573-58-2 CAPLUS
 CN Benzonitrile, 4-((1H-imidazol-4-yl)-2-naphthalenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1994:534112 CAPLUS
 DOCUMENT NUMBER: 121:134112
 TITLE: Preparation of imidazolymethylenetetralones and analogs as aromatase inhibitors
 INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton
 PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940414	WO 1993-JP1433	19931006
W: AU, BB, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPL. INFO.:			JP 1992-267130	A 19921006
			WO 1993-JP1433	W 19931006
OTHER SOURCE(S):		MARPAT 121:134112		
GI				




AB The title compds. I [R represents hydrogen, C1-C4 lower alkoxy, nitro or C1-C4 lower alkoxycarbonyl; when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, Z represents hydrogen and the broken line represents an arbitrary bond; when X represents hydrogen, Y and Z are combined together to represent a single bond; n represents an integer of 0 or 1] are prepd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H₂SO₄ was heated for 20 h at 80-90.degree. to give, after workup, (E)-2-(4-imidazolymethylene)-1-tetralone (II). II in vitro showed IC₅₀ of 0.260 μ M against aromatase.
 IT 157058-44-1P 157058-45-2P 157058-46-3P
 157058-47-4P 157058-52-1P 157058-53-2P
 157058-54-3P 157058-55-4P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
 (prepn. of, as aromatase inhibitor)

RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




L6 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 157058-45-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 157058-53-2 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]-


L6 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)




RN 157058-54-3 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)




RN 157058-55-4 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
HO₂C-CH₂-O



RN 150559-29-8 CAPLUS
CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:671157 CAPLUS
DOCUMENT NUMBER: 119:271157
TITLE: Fused benzeneacycetic acid derivative PG12 receptor agonists
INVENTOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Tokumoto, Hidekado
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 110 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 548949	A2	19930630	EP 1992-121898	19921223
EP 548949	A3	19931006		
EP 548949	B1	19970917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 05178832	A2	19930720	JP 1991-360502	19911227
JP 07025854	A2	19950127	JP 1992-209587	19920714
US 5461045	A	19951024	US 1992-912999	19920714
CA 2073917	AA	19940116	CA 1992-2073917	19920715
CA 2085844	AA	19930628	CA 1992-2085844	19921218
AT 158282	E	19971015	AT 1992-121898	19921223
ES 2108076	T3	19971216	ES 1992-121898	19921223
US 5389666	A	19950214	US 1992-997492	19921228
JP 07145057	A2	19950606	JP 1992-360608	19921228
JP 3419009	B2	20030623		
US 5589496	A	19961231	US 1994-334395	19941103
US 5849919	A	19981215	US 1996-722456	19960927
US 5962439	A	19991005	US 1998-168424	19981007
PRIORITY APPL. INFO.: JP 1991-360502 A 19911227				
JP 1992-209587 A 19920714				
US 1992-997492 A3 19921228				
US 1994-334395 A3 19941103				
US 1996-722456 A3 19960927				

OTHER SOURCE(S): MARPAT 119:271157
GI For diagram(s), see printed CA issue.
AB The title compds. I [A = (un)substituted heterocyclyl; B = alkylene, alkenylene; ring D = carbocyclic ring; R1 = HO, Cl-12 alkoxy, (un)substituted amino], which demonstrate PG12 receptor agonist activity and are useful in the treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer, or hypertension (no data), are prepd. and 1-contg. formulations presented. Thus, pyrazole deriv. II was prepd. which demonstrated 50% inhibitory concn. against human blood platelet aggregation of 0.043 .mu.M in human blood-derived. platelet-rich plasma.
IT 150558-87-5 150559-29-8
RL: RCT (Reactant); RACT (Reactant or reagent)
RN 150558-87-5 CAPLUS
CN Acetic acid, [[5,6,7,8-tetrahydro-6-(1H-imidazol-4-ylmethyl)-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)


L6 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:649949 CAPLUS
DOCUMENT NUMBER: 119:249949
TITLE: Preparation of imidazole derivatives as interleukin 1 inhibitors and antiplogistics
INVENTOR(S): Ueno, Yoshihide; Masumori, Hiroaki; Saji, Kitaro
PATENT ASSIGNEE(S): Sumitomo Pharma, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05155882	A2	19930622	JP 1991-348294	19911203
PRIORITY APPL. INFO.: JP 1991-348294 19911203				

OTHER SOURCE(S): MARPAT 119:249949
GI For diagram(s), see printed CA issue.
AB The title derivs. I [A = lower alkylene; M = arom. hydrocarbon ring, thiophene; D = O, CO, CH(OR5), C(=NOR5), CH(N(R5)2), NR5, single bond; R1 = H, halo; R2 = lower alkyl or alkenyl, (un)substituted phenyl, (un)substituted cycloalkyl, (un)substituted thienyl; R3 = M-contg. heterocyclyl; R4, R5 = H, lower alkyl; when D is single bond then R2 is lower alkyl] or their acid salts are prepd. as interleukin 1 inhibitors and antiplogistics. A mixt. of 3-(2-fluoro-4-biphenyl)-1-(4-pyridylcarbonyl)amino-2-butanone (prepd. from fluorobiphenol in 4 steps), and NH4Ac was heated at 140-150.degree. for 4 h to give 44% 4-(1-(2-fluoro-4-biphenyl)ethyl)-2-(4-pyridyl)imidazole-HCl. I inhibited growth of interleukin 1.
IT 150972-40-OP
RL: SPW (Synthetic preparation); PREP (Preparation)
(prepn. of, as interleukin 1 inhibitor and antiplogistics)
RN 150972-40-0 CAPLUS
CN 2-Naphthalenol, 6-[1-[2-(4-pyridinyl)-1H-imidazol-4-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




L6 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1992:106173 CAPLUS
 DOCUMENT NUMBER: 116:106173
 TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazole and imidazole analogs
 AUTHOR(S): Amemiya, Yoshiy; Hong, Seoung S.; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl; Feller, Dennis R.; Hsu, Fu Lian; Miller, Duane D.
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
 SOURCE: Journal of Medicinal Chemistry (1992), 35(4), 750-5
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Analogs I-III (R = 1-naphthyl, 2-naphthyl; R1 = H, Me) of medetomidine and naphazoline were synthesized and evaluated for their .alpha.1 (aorta) and .alpha.2 (platelet) activities. In general the 1-naphthalene analogs were the most potent inhibitors of epinephrine-induced platelet aggregation. Of considerable interest was the fact that I-III (R = 1-naphthyl) were antagonists in an .alpha.1-adrenergic system (aorta). Thus, appropriately substituted naphthalene analogs of medetomidine and naphazoline provide a spectrum of .alpha.1-agonist, .alpha.1-antagonist, and .alpha.2-antagonist activity.


IT 137967-82-9p 137967-88-5p
 RL: SPM (Synthetic preparation); PREP (Preparation)
 (prepn. and adrenergic activity of)
 RN 137967-82-9 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 137967-88-5 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1992:15364 CAPLUS
 DOCUMENT NUMBER: 116:15364
 TITLE: Structure-activity studies of new imidazolines on adrenoceptors of rat aorta and human platelets
 AUTHOR(S): Venkataraman, B. V.; Shams, G.; Hamada, A.; Amemiya, Y.; Tantishaiyakul, V.; Hsu, F.; Fashempour, J.; Romstedt, K. J.; Miller, D. D.; et al.
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
 SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1991), 344(4), 454-63
 CODEN: NSAPCC; ISSN: 0028-1298
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Potencies of new arom. substituted fluoro or iodo analogs of catecholimidazole (I) on functional responses in rat aorta (.alpha.1) and platelets (.alpha.2) were quantified. When compared either on the basis of EC50 or the disocn. const. (KA), 5-fluorocatecholimidazole was as potent as the ref. .alpha.1-adrenoceptor agonist, phenylephrine in the vascular tissue. The max. contraction of aorta produced by the fluoro analog was, however, 17% higher than that of phenylephrine. The time required for 1/2 relaxation of the tissue after 5-fluoro hydroxy imidazole was at least twice as long as that of the phenylephrine. The catechol moiety as well as fluorine substitution at the crit. 5-position of the arom. ring is essential for higher .alpha.1 adrenoceptor-mediated potency. As compared to the fluoro analogs, the adrenoceptor-mediated potencies of iodo-analogs were relatively weak on vascular tissue. Naphazoline and its analogs were partial agonists on vascular tissue with disocn. consts. which ranged from 110 to 2600 nmol/L. Imidazole analogs (II, R = naphthyl or xylene), were generally less potent agonist than the imidazolines by one order of magnitude. The vascular effects of all agonists were competitively blocked by prazosin with KB values which ranged from 0.04 to 0.48 nmol/L. Since the variation in KB values were within normal limits, the action of new imidazolines on rat aorta appears to be mediated mainly by the activation of the .alpha.1-adrenoceptor. Prazosin 10 nmol/L abolished the vascular response of some partial agonists. This indicates a slightly different mode of interaction of agonists with the transduction process. Carbon 4-substituted imidazolines produced little or no .alpha.1 adrenoceptor-mediated intrinsic activity, but competitive receptor blocking potency was comparable to that of phenolamine. Medetomidine was a partial agonist on the rat aorta with a KA of 260 nmol/L. When investigated as a blocker, the KB of medetomidine against phenylephrine was approx. 5600 nmol/L. The variation in the latter value was high. In acetylsalicylic acid-treated human platelets, the .alpha.2-adrenoceptor-mediated aggregatory effect of all fluoro analogs was weak. Iodo or naphazoline analogs did not initiate platelet

L6 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 aggregation but blocked the aggregation induced by epinephrine. The affinity of naphazoline for the .alpha.2-adrenoceptor was 1100 nmol/L. The IC50 of medetomidine for platelet anti-aggregatory effect was 3300 nmol/L, which compares favorably with other imidazole type of blockers of platelet aggregations. Sympathomimetic vasoconstrictor actions and platelet aggregation effects of these compds. can be dissociated. Some vasoconstrictors were antiaggregatory. The structure-activity relationships of the two receptor systems, namely rat aorta (.alpha.1) and platelets (.alpha.2), are discussed.
 IT 137967-88-5
 RL: BIOL (Biological study)
 (.alpha.-adrenoceptors of aorta and human platelets interaction with, structure in relation to)
 RN 137967-88-5 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1991:623482 CAPLUS
 DOCUMENT NUMBER: 115:223482
 TITLE: Use of 5-HT₃ receptor antagonists for treatment of
 panic disorders, agoraphobia, or obsessive compulsive
 disorders
 INVENTOR(S): Azcona, Alberto
 PATENT ASSIGNEE(S): Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.,
 Austria; Sandoz-Patent-G.m.b.H.; Sandoz A.-G.
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9012569	A1	19901101	WO 1990-EP540	19900406
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2031214	AA	19901022	CA 1990-2031214	19900406
AU 9054158	A1	19901116	AU 1990-54158	19900406
AU 631632	B2	19921203		
EP 422154	A1	19910417	EP 1990-905482	19900406
EP 422154	B1	19931201		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 03505881	T2	19911219	JP 1990-505770	19900406
JP 06069963	B4	19940507		
AT 97803	E	19931215	AT 1990-905482	19900406
ES 2061024	T3	19941201	ES 1990-905482	19900406
ZA 9003015	A	19911224	ZA 1990-3015	19900420
US 5530008	A	19960625	US 1994-187413	19940124

PRIORITY APPLN. INFO.:
 GB 1989-9147 19890421
 GB 1989-16602 19890720
 EP 1990-905482 19900406
 WO 1990-EP540 19900406
 US 1990-635156 19901219

AB 5-HT₃ receptor antagonists are useful in treating panic disorders and/or agoraphobia or obsessive compulsive disorders. Formulations for tablets, i.v. solns. and capsules are presented.

IT 135716-73-3
 RL: BIOL (Biological study)
 (5-HT₃ receptor antagonist)
 RN 135716-73-3 CAPLUS
 CN 1(2H)-Phenanthrene, 3,4-dihydro-2-[(5-methyl-1H-imidazol-4-yl)methyl]-
 (9CI) (CA INDEX NAME)




L6 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1990:198377 CAPLUS
 DOCUMENT NUMBER: 112:198377
 TITLE: Preparation and formulation of imidazole derivatives
 as 5-HT₃ receptor antagonists
 INVENTOR(S): North, Peter Charles; Oxford, Alexander William;
 Coates, Ian Harold
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 336759	A1	19891011	EP 1989-303415	19890406
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 02049772	A2	19900220	JP 1989-87841	19890406
US 5116984	A	19920526	US 1989-333967	19890406

PRIORITY APPLN. INFO.:
 GB 1988-8085 19880407
 GB 1988-8086 19880407

OTHER SOURCE(S): MARPAT 112:198377
 GI



AB Title compds. I (R1, R2 = H, halo, HO, Cl-4 alkoxy, Cl-4 alkyl, Cl-4 alkylthio, R3R4N, R3, R4 = H, Cl-4 alkyl, R3R4N = satd. 5-7-membered ring; A = CH, N; Im = substituted imidazolyl; n = 1-3) and physiol. acceptable salts and solvates thereof, potent and selective antagonists of 5-HT₃ receptors and useful, e.g., in treatment of psychotic disorders, anxiety, and nausea and vomiting (no data), are prepd. 1,2-Dihydro-3-[(5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl)methylene]-4(3H)-phenanthrene (prepn given) was dehydrogenated over Pd/C to give I (R1, R2 = H; A = CH; Im = 5-methylimidazol-4-yl; n = 2) which was converted to the maleate. Tablet and injection formulations were given.


IT 126737-68-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as 5-HT antagonist)
 RN 126737-68-6 CAPLUS
 CN 4(1H)-Phenanthrene, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-,
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 126737-65-3
 CMF C19 H18 N2 O

L6 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


L6 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CH 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.





IT 126737-65-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as HT₃-receptor antagonist)
 RN 126737-65-3 CAPLUS
 CN 4(1H)-Phenanthrene, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-
 (9CI) (CA INDEX NAME)



L6 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1990:139033 CAPLUS
 DOCUMENT NUMBER: 112:139033
 TITLE: Preparation of imidazole derivatives as drugs
 INVENTOR(S): Kihara, Noriaki; Tomino, Ikuo; Tan, Hiroaki; Takei, Mitsusachi
 PATENT ASSIGNEE(S): Mitsui Petrochemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01242571	A2	19890927	JP 1988-65731	19880322
PRIORITY APPLN. INFO.: JP 1988-65731 19880322				
OTHER SOURCE(S): MARPAT 112:139033				
GI				

L6 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title deriva. I or II (R1 = H, Ph; R2-R5 = H, OH, lower alkyl, lower alkoxy, lower alkylamino, halo; R2-R5 may be bonded to from rings; R6, R7 = H, lower alkyl, halo; X = O, S), useful as cerebral function improvers, antihypertensives, diuretics, etc. (no data), are prepd. by acid-catalyzed reaction of (hydroxymethyl)imidazoles III or their acid salts with benzenes IV or 5-membered heterocycle V. Thus, aq. III.HCl (R1 = H) was treated with 1,3,5-C6H3Me3 and 4-MeC6H4SO3H at 170.degree. for 7 h to give 76% I (R1 = R2 = H, R3-R5 = 2,4,6-Me3).



IT 125883-69-4P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as drug)

RN 125883-69-4 CAPLUS

CN 1H-imidazole, 4-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1979:168771 CAPLUS
 DOCUMENT NUMBER: 90:168771
 TITLE: Photochemical reactions. Photochemistry of N-acylimidazoles. V. Photolysis of the N-acylimidazoles of dehydroabiatic acid and of 13-deisopropyl-10-epi-dehydroabiatic acid
 AUTHOR(S): Iwasaki, Shigeo
 CORPORATE SOURCE: Org.-Chem. Lab., ETH, Zurich, Switz.
 SOURCE: Helvetica Chimica Acta (1978), 61(8), 2843-50
 CODEN: HCACAV; ISSN: 0018-019X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

L6 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Irradn. of I gave no Type II elimination, but gave II and III by migration of the imidazolylcarbonyl group, probably via a cyclobutanol intermediate. Similarly, irradn. of IV gave only a small amt. of Type II fragmentation, the main products being derived from .gamma.-H abstraction.

IT 69634-29-3P
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 69634-29-3 CAPLUS


CN Methanone, 1H-imidazol-4-yl[4b,5,6,7,8,8a,9,10-octahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1973:515495 CAPLUS
 DOCUMENT NUMBER: 79:115495
 TITLE: Synthesis of small molecule catalysts. Model for the active site of ribonuclease-A
 AUTHOR(S): Algieri, Aldo A.
 CORPORATE SOURCE: Cornell Univ., Ithaca, NY, USA
 SOURCE: (1973) 116 pp. Avail.: Univ. Microfilms, Ann Arbor, Mich., Order No. 73-14,715
 From: Diss. Abstr. Int. B 1973, 33(12) (Pt. 1), 5722
 DOCUMENT TYPE: Dissertation
 LANGUAGE: English
 AE Unavailable
 IT 49738-45-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (as model for the active site of ribonuclease A)
 RN 49738-45-6 CAPLUS
 CN 1H-imidazole-4-ethanamine, N-[[3-(1H-imidazol-4-ylmethyl)-1-naphthalenyl]methyl]-, conjugate diacid (9CI) (CA INDEX NAME)



● 2 H⁺

L6 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1972:501463 CAPLUS
 DOCUMENT NUMBER: 77:101463
 TITLE: Voges-Frogekauer reaction. II. Structure of a pigment from the diacetyl reaction of 1-benzyl-1-methylguanidine
 AUTHOR(S): Nishimura, Tamio; Yamazaki, Chiji; Ueno, Tetsuro; Kitajima, Shinichi; Ishige, Koichi
 CORPORATE SOURCE: Sch. Hyg. Sci., Kitasato Univ., Tokyo, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1972), 45(6), 1782-5
 CODEN: BCSJAB; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A pigment formed by the reaction of 1-benzyl-1-methylguanidine was isolated as reddish purple prisms. The reduced pigment was colorless and rapidly converted back to the original pigment on exposure to the air. On the basis of ir, NMR, and mass spectral evidence, the structures of the pigment and the reduced form were established to be 2-(N-benzyl-N-methylamino)-4-methyl-5-(1-oxo-1,2-dihydro-2-naphthylidenemethyl)imidazole and 5-(1-hydroxy-2-naphthylmethyl)imidazole, resp.
 IT 37842-56-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 37842-56-1 CAPLUS
 CN 1-Naphthalenol, 2-[[5-methyl-2-[[methyl(phenylmethyl)amino]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

161.62

338.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-22.18

-22.18

STN INTERNATIONAL LOGOFF AT 08:01:11 ON 13 JAN 2004